CY1113344T1 - Use of IL-21 in Cancer and Monoclonal Antibodies for Solid Cancer Therapeutic Treatment - Google Patents

Use of IL-21 in Cancer and Monoclonal Antibodies for Solid Cancer Therapeutic Treatment

Info

Publication number
CY1113344T1
CY1113344T1 CY20121100454T CY121100454T CY1113344T1 CY 1113344 T1 CY1113344 T1 CY 1113344T1 CY 20121100454 T CY20121100454 T CY 20121100454T CY 121100454 T CY121100454 T CY 121100454T CY 1113344 T1 CY1113344 T1 CY 1113344T1
Authority
CY
Cyprus
Prior art keywords
cancer
monoclonal antibodies
therapeutic treatment
molecules
solid
Prior art date
Application number
CY20121100454T
Other languages
Greek (el)
Inventor
Andrew J Nelson
Steven D Hughes
Richard D Holly
Wayne R Kindsvogel
Original Assignee
Zymogenetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03757366A external-priority patent/EP1531850B1/en
Application filed by Zymogenetics, Inc. filed Critical Zymogenetics, Inc.
Publication of CY1113344T1 publication Critical patent/CY1113344T1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Περιγράφονται μέθοδοι για τη θεραπευτική αγωγή θηλαστικών με καρκίνο και μολύνσεις χρησιμοποιώντας μόρια που έχουν μια λειτουργική δραστικότητα της IL-21. Τα μόρια που έχουν λειτουργικές δραστικότητες της IL-21 περιλαμβάνουν πολυπεπτίδια που έχουν ομολογία προς την ανθρώπινη IL 21 πολυπεπτιδική αλληλουχία και πρωτεΐνες συντηγμένες προς ένα πολυπεπτίδιο με λειτουργική δραστικότητα της IL-21. Τα μόρια μπορούν να χρησιμοποιηθούν ως μονοθεραπεία ή σε συνδυασμό με άλλες γνωστές θεραπευτικές αγωγές καρκίνου ή ιϊκές θεραπευτικές αγωγές.Methods are described for the treatment of mammals with cancer and infections using molecules that have a functional activity of IL-21. Molecules having IL-21 functional activities include polypeptides that have homology to the human IL 21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as monotherapy or in combination with other known cancer treatments or viral treatments.

CY20121100454T 2002-06-07 2012-05-16 Use of IL-21 in Cancer and Monoclonal Antibodies for Solid Cancer Therapeutic Treatment CY1113344T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38712702A 2002-06-07 2002-06-07
EP03757366A EP1531850B1 (en) 2002-06-07 2003-06-06 Use of IL-21 and monoclonal antibody for treating solid cancers

Publications (1)

Publication Number Publication Date
CY1113344T1 true CY1113344T1 (en) 2016-06-22

Family

ID=58448866

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100454T CY1113344T1 (en) 2002-06-07 2012-05-16 Use of IL-21 in Cancer and Monoclonal Antibodies for Solid Cancer Therapeutic Treatment

Country Status (1)

Country Link
CY (1) CY1113344T1 (en)

Similar Documents

Publication Publication Date Title
WO2003103589A3 (en) Use of il-21 in cancer and other therapeutic applications
CY1120070T1 (en) METHOD OF THERAPEUTIC TREATMENT WITH THE USE OF ANTI-ERBB-METHYSINEOID ANTIBODY conjugates
DE602004011770D1 (en) FUSION PROTEIN
EA200001023A1 (en) SPECIFIC FOR FAPA- (PROTEIN ALPHA FIBROBE ACTIVATION) ANTIBODY WITH INCREASED PRODUCTIVITY
DE69630890D1 (en) PEPTID-IMITATING SUBSTANCES IN CANCER THERAPY
DE60032486D1 (en) PRION PROTEIN PEPTIDES AND ITS USE
CY1117387T1 (en) Monoclonal N-11 Dispersed β-Amyloid Antibodies, COMPOSITIONS, METHODS AND USES
DK0914144T3 (en) Therapeutic uses of BPI protein products for human meningococcemia
CY1105616T1 (en) PEPTIDE INHIBITORS OF TGFβ1
EA200100749A1 (en) SYNTHETIC PEPTIDES OWN SURFACE ACTIVITY AND THEIR APPLICATION FOR THE PREPARATION OF THE SYNTHETIC SURFACTANT
CY1112639T1 (en) ORTHOLOGICALLY DESIGNED ANTIBODIES
HUP9802212A2 (en) Recombinant anti-cd4 antibodies for human therapy
CR7875A (en) IMMUNOGLOBIN VARIANTS AND USES OF THIS
HK1069316A1 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
ATE482972T1 (en) TGF-BETA1 BINDING AND SUPPORTED PEPTIDES
BRPI0514115A (en) combination therapy employing transferrin fusion proteins comprising glp-1
ATE88900T1 (en) INTERFERON ALPHA CONJUGATES WITH IMMUNOGLOBULINS.
EA200500218A1 (en) TREATMENT OF KIDNEY INSUFFICIENCY WITH THE USE OF INTERFERON-β
CY1108459T1 (en) AKT-3 NUCLEAR ACIDS, POLYPALPTESES, AND THEIR USES
MXPA05008704A (en) Fusion proteins of interferon alpha muteins with improved properties.
HUP0302566A2 (en) Compositions and methods for the therapy and diagnosis of breast cancer
ATE450272T1 (en) BORDETELLA RECOMBINANT ADENYLATE CYCLASE TOXIN INDUCES T CELL RESPONSES AGAINST TUMORAL ANTIGENS
ATE368687T1 (en) THROMBOPOIETIN PROTEINS WITH IMPROVED PROPERTIES
IT1249684B (en) HEPATITIS VIRUS PROTEIN ENV EPITOPES
CY1113344T1 (en) Use of IL-21 in Cancer and Monoclonal Antibodies for Solid Cancer Therapeutic Treatment